登录 | 注册    关注公众号  
微信公众号
搜索
 > 【Fusion glycoprotein】

Fusion glycoprotein信息

英文名称:Respiratory syncytial virus F protein
中文名称:呼吸道合胞病毒F蛋白
靶点别称:Protein F,F,Fusion glycoprotein F0
上市药物数量:3
临床药物数量:4
最高研发阶段:批准上市

Fusion glycoprotein分子别名

Fusion glycoprotein, F protein, F, Nipah virus, Hendra virus

Fusion glycoprotein分子背景

Hendra virus (HeV) and Nipah virus (NiV) are henipaviruses discovered in the mid-to late 1990s that possess a broad host tropism and are known to cause severe and often fatal disease in both humans and animals. HeV and NiV infect host cells through the coordinated efforts of two envelope glycoproteins. The G glycoprotein attaches to cell receptors, triggering the fusion (F) glycoprotein to execute membrane fusion. G is a type II homotetrameric transmembrane protein responsible for binding to ephrinB2 or ephrinB3 (ephrinB2/B3) receptors. F is a homotrimeric type I transmembrane protein that is synthesized as a premature F0 precursor and cleaved by cathepsin L during endocytic recycling to yield the mature, disulfide-linked, F1 and F2 subunits. Upon binding to ephrinB2/B3, NiV G undergoes conformational changes leading to F triggering and insertion of the F hydrophobic fusion peptide into the target membrane. Subsequent refolding into the more stable post-fusion F conformation drives merger of the viral and host membranes to form a pore for genome delivery to the cell cytoplasm.

Fusion glycoprotein上市药物信息

英文名称 中文名称 研发代码 研发阶段 公司 最早商品名 最早批准国家 最早适应症 最早批准公司 最早批准日期 适应症 临床试验
Nirsevimab 尼塞韦单抗 SP-0232; MEDI-8897; Anti-RSV MAb-YTE; Anti-RSV-mAb-D25 批准上市 Aimm Therapeutics, 赛诺菲, MedImmune Inc Beyfortus EU 呼吸道合胞体病毒感染 Astrazeneca Ab 2022-10-31 下呼吸道感染, 呼吸道合胞体病毒感染 详情
Palivizumab 帕利珠单抗 ABT-315; MEDI-493 批准上市 艾伯维, Medimmune Llc Synagis United States 呼吸道合胞体病毒感染 Swedish Orphan Biovitrum Ab (Publ) 1998-06-19 支气管肺发育不良, 呼吸道合胞体病毒感染, 早产儿疾病, 先天性心脏缺损, 早产(孕37周前) 详情
Respiratory syncytial virus immune globulin RSV-IGIV 批准上市 Medimmune RespiGam United States 呼吸道合胞体病毒感染 null 1996-01-01 呼吸道合胞体病毒感染 详情

Fusion glycoprotein临床药物信息

英文名称 研发代码 研发阶段 公司 适应症 临床试验
CPI-RSV-F Vaccine BLB-201 临床二期 Blue Lake Biotechnology Inc 呼吸道合胞体病毒感染 详情
GR-2102 GR2102; GR-2102 临床一期 智翔(上海)医药科技有限公司, 重庆智翔金泰生物制药股份有限公司 呼吸道合胞体病毒感染 详情
Palivizumab biosimilar (mAbxience) 临床一期 Mabxience Sa 详情

消息提示

请输入您的联系方式,再点击提交!

确定